DST/NRF Centre of Excellence for Biomedical Tuberculosis Research, MRC Centre for Molecular and Cellular Biology, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Tygerberg 7505, South Africa.
Comp Immunol Microbiol Infect Dis. 2013 May;36(3):287-94. doi: 10.1016/j.cimid.2012.07.003. Epub 2012 Aug 23.
Vaccination has been spectacularly successful in eradicating or controlling some infectious diseases, and is particularly attractive as an approach to tackling other infectious diseases. Although vaccination against tuberculosis has been done for nearly 100 years, it is clearly not that successful since the disease still occurs at epidemic levels in animals and humans in many areas. New approaches to vaccination against TB in humans and animals are currently in the pipeline, but none show either complete protection or sterilization. However, there is evidence to suggest that vaccination may deliver some positive outcomes. Not only should we be investigating new vaccines, but also how vaccines and candidates are used and delivered. There are many reasons to think that this task will not be simple, or perhaps not possible in some cases. We present different aspects of the development of vaccines against TB, outline some complications and suggest some new ways to consider this problem.
疫苗接种在消除或控制某些传染病方面取得了巨大成功，作为一种应对其他传染病的方法尤其具有吸引力。尽管近 100 年来一直在对结核病进行疫苗接种，但显然它并不那么成功，因为这种疾病在许多地区的动物和人类中仍以流行的方式发生。目前正在研发针对人类和动物结核病的新疫苗接种方法，但没有一种方法显示出完全的保护或绝育效果。然而，有证据表明疫苗接种可能会带来一些积极的结果。我们不仅应该研究新疫苗，还应该研究疫苗和候选疫苗的使用和传递方式。有很多理由认为，这项任务并不简单，或者在某些情况下可能无法完成。我们介绍了针对结核病疫苗的不同发展方面，概述了一些复杂性，并提出了一些考虑这个问题的新方法。
